2. Signaling Pathways
  3. Neuronal Signaling
  4. Transthyretin (TTR)

Transthyretin (TTR)

thyroxine-binding prealbumin

Transthyretin (TTR), formerly known as thyroxine-binding prealbumin, is a tetrameric protein transporting hormones in the plasma and brain. It forms a complex with retinol-binding protein (RBP), which facilitates the transport of thyroid hormones and vitamin A in the blood and cerebrospinal fluid. TTR is a positive indicator of nutrition status and is negatively correlated with inflammation. TTR is a neuroprotective and oxidative-stress-suppressing factor. The TTR structure is destabilized by mutations, oxidative modifications, aging, proteolysis, and metal cations, including Ca2+. Destabilized TTR molecules form amyloid deposits, resulting in senile and familial amyloidopathies.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-132609
    Patisiran sodium
    		99.09%
    Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis.
    Patisiran sodium
  • HY-132608
    Inotersen sodium
    Inotersen (ISIS-420915) sodium is a 2′-O-methoxyethyl-modified antisense oligonucleotide. Inotersen sodium inhibits the production of transthyretin (TTR) protein by targeting the TTR RNA transcript and reduces the levels of the TTR transcript. Inotersen sodium can be used for the research of hereditary TTR amyloidosis polyneuropathy.
    Inotersen sodium
  • HY-N1957
    Gamma-Mangostin
    		Inhibitor 99.91%
    Gamma-Mangostin is a novel competitive 5-hydroxytryptamine 2A (5-HT2A) receptor antagonist and potent epoxidase 2 (COX-2) inhibitor, as well as a transthyroxin protein (TTR) profibrosis inhibitor. Gamma-Mangostin binds to the thyroxine (T4)-binding sites and stabilized the TTR tetramer. Gamma-Mangostin inhibits [3H] spiperone binding to cultured rat aortic myocytes (IC50=3.5 nM) and reduces The perfusion pressure response of rat coronary artery to 5-HT2A (IC50=0.32 μM). Gamma-Mangostin has anti-inflammatory, antibacterial, antioxidant and anticancer activities, and can be used in the study of metabolic disorders such as diabetes.
    Gamma-Mangostin
  • HY-113283
    Homogentisic acid
    		Activator 99.68%
    Homogentisic acid is an orally active, blood-brain barrier-permeable amyloidogenic compound that functions as both an amyloid component and a pigment precursor. Accumulation of homogentisic acid downregulates tight junction proteins (such as claudin-5, occludin, ZO-1) and impairs blood-brain barrier integrity. Homogentisic acid and its oxidation product benzoquinone acetic acid not only induce the aggregation and fibrosis of multiple proteins (such as Aβ1-42, α-synuclein, SAA, Transthyretin (TTR), atrial natriuretic peptide), but also trigger oxidative stress, damage to the Wnt/β-catenin pathway, and neurotoxicity, leading to ochronosis pigment deposition and synaptic dysfunction. At specific concentrations, homogentisic acid exerts no cytotoxicity or genotoxicity on human peripheral blood lymphocytes, and even counteracts the genotoxicity induced by Irinotecan (HY-16562). Homogentisic acid serves as an important tool molecule for investigating the mechanisms of diseases including ochronosis, secondary amyloidosis, Alzheimer's disease, and colorectal cancer.
    Homogentisic acid
  • HY-107633
    A 1120
    		99.73%
    A 1120 is a high-affinity nonretinoid retinol-binding protein 4 (RBP4) antagonist with a Ki value of 8.3 nM. A 1120 disrupts the interaction between RBP4 and its binding partner transthyretin.
    A 1120
  • HY-148089C
    Eplontersen sodium scrambled negative control
    		Inhibitor
    Eplontersen sodium scrambled negative control is the sequence scrambled negative control of Eplontersen sodium.
    Eplontersen sodium scrambled negative control
  • HY-177650B
    Nucresiran sodium scrambled negative control
    		Inhibitor
    Nucresiran sodium scrambled negative control is the sequence scrambled negative control of Nucresiran sodium.
    Nucresiran sodium scrambled negative control
  • HY-132590C
    Revusiran sodium scrambled negative control
    		Inhibitor
    Revusiran sodium scrambled negative control is the sequence scrambled negative control of Revusiran sodium.
    Revusiran sodium scrambled negative control
  • HY-132589
    Vutrisiran
    Vutrisiran (ALN-TTRsc02) is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran can be used for transthyretin (TTR)-mediated amyloidosis research.
    Vutrisiran
  • HY-132589A
    Vutrisiran sodium
    		Inhibitor
    Vutrisiran sodium (ALN-TTRsc02 sodium) is a liver-directed small interfering RNA (siRNA). Vutrisiran sodium targets the mRNA of transthyretin (TTR), and is applicable to studies on transthyretin (TTR)-mediated amyloidosis.
    Vutrisiran sodium
  • HY-14852A
    Tafamidis meglumine
    		99.79%
    Tafamidis meglumine (Fx-1006A) is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis meglumine inhibits amyloidogenesis.
    Tafamidis meglumine
  • HY-109165
    Acoramidis
    		98.47%
    Acoramidis (AG10) is an orally active and selective kinetic stabilizer of WT and V122I-TTR (transthyretin). Acoramidis (AG10) is used in the study for transthyretin amyloidosis.
    Acoramidis
  • HY-148089A
    Eplontersen sodium
    		Inhibitor
    Eplontersen sodium the sodium salt form of Eplontersen (HY-148089). Eplontersen sodium is a triantennary N-acetyl galactosamine (GalNAc3-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases.
    Eplontersen sodium
  • HY-132590A
    Revusiran sodium
    		Inhibitor
    Revusiran (ALN-TTRSC) sodium is an RNA interference agent targeting the mRNA of transthyretin (Transthyretin, TTR). Revusiran sodium mediates sequence-specific degradation of TTR mRNA through RNA interference, reduces the synthesis of TTR protein, binds to GalNAc ligands, and is taken up by hepatocytes via the asialoglycoprotein receptor. Revusiran sodium exhibits favorable nonclinical safety profiles. Revusiran sodium can be used in studies related to transthyretin-mediated amyloidosis.
    Revusiran sodium
  • HY-112974
    Inotersen
    		Inhibitor
    Inotersen (GSK-2998728; ISIS-420915) is a 2'-O-methoxyethyl-modified antisense oligonucleotide and transthyretin (TTR) inhibitor with low genotoxicity. Inotersen triggers RNase H1-mediated degradation by binding to TTR mRNA, thereby effectively reducing the production of both mutant and wild-type transthyretin in the liver. Inotersen significantly reduces amyloid fiber deposition, yet specific toxicities such as inflammation or tumors are observed at high doses in some animal models. Inotersen is used in studies of hereditary transthyretin amyloidosis and the associated polyneuropathy and cardiomyopathy.
    Inotersen
  • HY-P990734
    Coramitug
    		Inhibitor 99.00%
    Coramitug is an anti-TTR human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Coramitug
  • HY-148089
    Eplontersen
    		Inhibitor 98.70%
    Eplontersen is a triantennary N-acetyl galactosamine (GalNAc3-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases.
    Eplontersen
  • HY-153609
    AS-Patisiran sodium
    		Inhibitor
    AS-Patisiran sodium is an antisense strand of Patisiran. Patisiran is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran can be used for the research of hereditary TTR amyloidosis.
    AS-Patisiran sodium
  • HY-P991128
    Cliramitug
    Cliramitug (NI-006; ALXN2220) is a monoclonal antibody that targets human transthyretin (TTR). Cliramitug binds to TTR and inhibits its amyloidogenic process, exerting amyloid formation-inhibiting activity. Cliramitug can be used in the research of transthyretin amyloidosis-related diseases, such as certain neurological and cardiovascular diseases.
    Cliramitug
  • HY-109165A
    Acoramidis hydrochloride
    		98.70%
    Acoramidis (AG10) hydrochloride is an orally active and selective kinetic stabilizer of WT and V122I-TTR (transthyretin). Acoramidis (AG10) hydrochloride is used in the study for transthyretin amyloidosis.
    Acoramidis hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity